57
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Increasing number of cases and outbreaks caused by Candida auris in the EU/EEA, 2020 to 2021

      research-article
      1 , 1 , 1 , Candida auris survey collaborative group 2 The Candida auris survey collaborative group includes the following national experts, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      Eurosurveillance
      European Centre for Disease Prevention and Control (ECDC)
      Europe, healthcare-associated infections, fungal infections, multidrug-resistance, outbreak, surveillance, Candida

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The number of cases of Candida auris infection or carriage and of countries reporting cases and outbreaks increased in the European Union and European Economic Area during 2020 and 2021. Eight countries reported 335 such cases in 2020 and 13 countries 655 cases in 2021. Five countries experienced outbreaks while one country reported regional endemicity. These findings highlight the need for adequate laboratory capacity and surveillance for early detection of C. auris and rapid implementation of control measures.

          Related collections

          Most cited references15

          • Record: found
          • Abstract: found
          • Article: not found

          Candida auris: a Review of the Literature

          The emerging pathogen Candida auris has been associated with nosocomial outbreaks on five continents. Genetic analysis indicates the simultaneous emergence of separate clades of this organism in different geographical locations. Invasive infection and colonization have been detected predominantly in patients in high-dependency settings and have garnered attention due to variable antifungal resistance profiles and transmission within units instituting a range of infection prevention and control measures. Issues with the identification of C. auris using both phenotypic and molecular techniques have raised concerns about detecting the true scale of the problem. This review considers the literature available on C. auris and highlights the key unknowns, which will provide direction for further work in this field.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Candida auris Outbreak in a COVID-19 Specialty Care Unit — Florida, July–August 2020

            On January 8, 2021, this report was posted online as an MMWR Early Release. In July 2020, the Florida Department of Health was alerted to three Candida auris bloodstream infections and one urinary tract infection in four patients with coronavirus disease 2019 (COVID-19) who received care in the same dedicated COVID-19 unit of an acute care hospital (hospital A). C. auris is a multidrug-resistant yeast that can cause invasive infection. Its ability to colonize patients asymptomatically and persist on surfaces has contributed to previous C. auris outbreaks in health care settings ( 1 – 7 ). Since the first C. auris case was identified in Florida in 2017, aggressive measures have been implemented to limit spread, including contact tracing and screening upon detection of a new case. Before the COVID-19 pandemic, hospital A conducted admission screening for C. auris and admitted colonized patients to a separate dedicated ward. Hospital A’s COVID-19 unit spanned five wings on four floors, with 12–20 private, intensive care–capable rooms per wing. Only patients with positive test results for SARS-CoV-2, the virus that causes COVID-19, at the time of admission were admitted to this unit. After patient discharge, room turnover procedures included thorough cleaning of all surfaces and floor and ultraviolet disinfection. In response to the four clinical C. auris infections, unit-wide point prevalence surveys to identify additional hospitalized patients colonized with C. auris were conducted during August 4–18; patients on all four floors were screened sequentially and rescreened only if their initial result was indeterminate. Hospital A’s infection prevention team, the Florida Department of Health, and CDC performed a joint investigation focused on infection prevention and control at hospital A that included observation of health care personnel (HCP) use of personal protective equipment (PPE), contact with and disinfection of shared medical equipment, hand hygiene, and supply storage. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.* Among 67 patients admitted to the COVID-19 unit and screened during point prevalence surveys, 35 (52%) received positive test results. Mean age of colonized patients was 69 years (range = 38–101 years) and 60% were male. Six (17%) colonized patients later had clinical cultures that grew C. auris. Among patients screened who had available medical records (20), two (10%) were admitted directly from a long-term care facility and eight (40%) died within 30 days of screening, but whether C. auris contributed to death is unknown (Table). TABLE Demographic and clinical characteristics of patients colonized with Candida auris in a COVID-19 specialty care unit identified during screening at an acute care hospital (N = 35) — Florida, August 4–18, 2020 Characteristic (no. with available information) No. (%)* Sex (35) Female 14 (40) Male 21 (60) Mean age, yrs (range) (35) 69 (38–101) Clinical culture with C. auris during admission † (35) 6 (17) Mortality within 30 days of screening § (20) 8 (40) Admitted from long-term care facility (20) 2 (10) Medical devices present at time of screening (20) Central venous catheter 16 (80) Ventilator 11 (55) Nasogastric/Gastric tube 11 (55) Urinary catheter 11 (55) Underlying conditions (20) Diabetes 12 (60) Chronic wound/wound care 4 (20) Malignancy 3 (15) Chronic kidney disease 3 (15) Chronic lung disease 1 (5) Cardiac disease 1 (5) No underlying conditions 4 (20) Known multidrug-resistant organism before screening (20) 5 (25) Vancomycin-resistant Enterococci 3 (15) Extended-spectrum beta-lactamase–producing Enterobacteriaceae 2 (10) Methicillin-resistant Staphylococcus aureus 2 (10) Carbapenem-resistant Enterobacteriaceae 0 (—) Candida auris 0 (—) Abbreviation: COVID-19 = coronavirus disease 2019. * Clinical information available for 20 (57%) of 35 patients. Medical records for other patients were not available. Clinical information on this subset might not be representative of all patients. † Results of clinical cultures with Candida auris finalized after colonization was identified by screening during patients’ current admission. § Contribution of C. auris to mortality is unknown. HCP in the COVID-19 unit were observed wearing multiple layers of gowns and gloves during care of COVID-19 patients. HCP donned eye protection, an N95 respirator, a cloth isolation gown, gloves, a bouffant cap, and shoe covers on entry to the COVID-19 unit; these were worn during the entire shift. A second, disposable isolation gown and pair of gloves were donned before entering individual patient rooms, then doffed and discarded upon exit. Alcohol-based hand sanitizer was used on gloved hands after doffing outer gloves. HCP removed all PPE and performed hand hygiene before exiting the unit. Investigators observed multiple opportunities for contamination of the base layer of gown and gloves during doffing and through direct contact with the patient care environment or potentially contaminated surfaces such as mobile computers. Mobile computers and medical equipment were not always disinfected between uses, medical supplies (e.g., oxygen tubing and gauze) were stored in open bins in hallways and accessed by HCP wearing the base PPE layer, and missed opportunities for performing hand hygiene were observed. A combination of factors that included HCP using multiple gown and glove layers in the COVID-19 unit, extended use of the underlayer of PPE, lapses in cleaning and disinfection of shared medical equipment, and lapses in adherence to hand hygiene likely contributed to widespread C. auris transmission. After hospital A removed supplies from hallways, enhanced cleaning and disinfection practices, and ceased base PPE layer practices, no further C. auris transmission was detected on subsequent surveys. The COVID-19 pandemic has prompted facilities to implement PPE conservation strategies during anticipated or existing shortages and to use PPE in ways that are not routine (e.g., extended wear and reuse) ( 8 ). Some health care facilities not experiencing shortages allow extra PPE layers because of the perception of increased protection for HCP. CDC does not recommend the use of more than one isolation gown or pair of gloves at a time when providing care to patients with suspected or confirmed SARS-CoV-2 infection ( 9 , 10 ). Such practices among HCP might be motivated by fear of becoming infected with SARS-CoV-2 but instead might increase risks for self-contamination when doffing and for transmission of other pathogens among patients and exacerbate PPE supply shortages. When managing SARS-CoV-2 patients in a dedicated ward, HCP should maintain standard practices (e.g., hand hygiene at indicated times and recommended cleaning and disinfection) intended to prevent transmission of other pathogens. † , § Outbreaks such as that described in this report highlight the importance of adhering to recommended infection control and PPE practices and continuing surveillance for novel pathogens like C. auris.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Worsening epidemiological situation of carbapenemase-producing Enterobacteriaceae in Europe, assessment by national experts from 37 countries, July 2018

              A survey on the epidemiological situation, surveillance and containment activities for carbapenemase-producing Enterobacteriaceae (CPE) was conducted in European countries in 2018. All 37 participating countries reported CPE cases. Since 2015, the epidemiological stage of CPE expansion has increased in 11 countries. Reference laboratory capability, dedicated surveillance and a specific national containment plan are in existence in 33, 27 and 14 countries, respectively. Enhanced control efforts are needed for CPE containment in Europe.
                Bookmark

                Author and article information

                Journal
                Euro Surveill
                Euro Surveill
                eurosurveillance
                Eurosurveillance
                European Centre for Disease Prevention and Control (ECDC)
                1025-496X
                1560-7917
                17 November 2022
                : 27
                : 46
                : 2200846
                Affiliations
                [1 ]European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
                [2 ]The members of the Candida auris survey collaborative group are listed under Collaborators and at the end of the article
                Author notes

                Correspondence: Anke Kohlenberg ( anke.kohlenberg@ 123456ecdc.europa.eu )

                Article
                2200846 2200846
                10.2807/1560-7917.ES.2022.27.46.2200846
                9673237
                36398575
                eb70cb88-83ee-47e2-9acb-f9188bd6a27b
                This article is copyright of the authors or their affiliated institutions, 2022.

                This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.

                History
                : 28 October 2022
                : 14 November 2022
                Categories
                Rapid Communication
                Custom metadata
                3

                europe,healthcare-associated infections,fungal infections,multidrug-resistance,outbreak,surveillance,candida

                Comments

                Comment on this article